Markel Insurance, part of the Markel Group, has launched a new clinical trials insurance product to support research and product development globally. The newly introduced offering is aimed at sponsors, researchers and participants involved in clinical trials, providing insurance coverage throughout all phases of research. The insurer stated that the product is tailored to align with the regulatory requirements of more than 100 territories. Markel's service offering includes same-day quotations, and expedited issuance of certificates and policy documents, leveraging an automated document production platform. Markel life science senior underwriter Robert Hannaford said: "At Markel, we understand the time-sensitive nature of these requests and have developed a compliant solution – backed by our expert underwriting and award-winning claims service, making sure clients are fully protected to carry out the clinical research of products worldwide. "We do not want insurance to be a delaying factor to allowing important clinical research to begin, which is why we have produced a customer-centric product that streamlines all parts of the insurance value chain to prioritise service.” The company leverages its Lloyd's licences and global network to meet compliance standards in the required jurisdictions. Hannaford added: "We look forward to supporting innovation in the life science industry by continuing to deliver effective risk transfer solutions for future lifesaving treatments through open communication, dialogue and transparency with our brokers, insureds and trading partners." Recently, Markel Group reported total operating income of $282.5m for the first quarter of 2025 (Q1 2025), a decrease from the $1.4bn recorded in Q1 the previous year. Diluted net income per common share was $12.08 in the quarter, versus $75.43 in Q1 2024. Total operating revenues for Markel Group also plunged to $3.4bn in Q1 2025, down 31.4% from $4.47bn in the prior year. "Markel unveils new insurance product for clinical trials " was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Markel unveils new insurance product for clinical trials
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...